Rhythm Biosciences Share Price and Company Fundamentals



Price
$1.125
Change
-0.020 (-1.747%)
52 week
0.16 - 1.675

Last traded: Last Friday at 6:10 AM

Rhythm Biosciences Limited engages in developing and commercializing medical diagnostics technology in Australia and internationally. It is developing ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.

Key Metrics

PE ratio

-

PB ratio

140.62

Dividend yield

Beta

4.10

Market cap

$234.9M

Enterprise value

$229.3M

Company profile

Primary activitiesResearch, development and commercialisation of medical diagnostic technology
Industry / SectorDiagnostics & Research / Healthcare
Websitehttp://www.rhythmbio.com
Mailing addressBio21 Institute 30 Flemington Road Parkville VIC 3010 Australia
Phone / Fax /
Share registryLINK MARKET SERVICES LIMITED

Dividends

Rhythm Biosciences does not pay dividends.

Company Executives

As of Sep 2021, following are the company executives and directors listed on Rhythm Biosciences.

NameTitleAgeTotal Pay
Mr. Glenn GilbertChief Exec. Officer384.87k
Dr. Trevor John Lockett Ph.D.Technical Director, Chair of the Clinical Advisory Board & Director112k
Mr. Adrien Michele Wing B.Acc, B.Bus, C.P.A., CPACompany Sec.46105.6k
Ms. Pauline MoffattJoint Company Sec.

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

-597.64%

Return on assets

-144.88%

Return on equity

-372.53%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Rhythm Biosciences is 234.9M and its enterprise value is 229.3M. The enterprise value to revenue ratio of RHY is 206.85.

The RHY's stocks Beta value is 4.10 making it 310% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Rhythm Biosciences (RHY)

Rhythm Biosciences (ASX:RHY) Frequently Asked Questions

1. What is Rhythm Biosciences's Stock Symbol?

Rhythm Biosciences trades on ASX under the ticker symbol "RHY".

2. What is Rhythm Biosciences's stock price today?

One share of RHY stock can currently be purchased for approximately $1.125.

3. How can I contact Rhythm Biosciences?

Rhythm Biosciences's mailing address is Bio21 Institute 30 Flemington Road Parkville VIC 3010 Australia. The company can be reached via phone at .

4. What is Rhythm Biosciences's official website?

The official website of Rhythm Biosciences is http://www.rhythmbio.com.

5. Which share registry manages Rhythm Biosciences's stock?

Rhythm Biosciences's stock is managed by LINK MARKET SERVICES LIMITED.